{
    "nctId": "NCT06609187",
    "briefTitle": "A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors",
    "officialTitle": "An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics or Preliminary Efficacy and Antitumor Activity of GNC-077 Multi-specific Antibody Injection in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer, Solid Tumor",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Phase Ia: Dose limiting toxicity (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Able to understand the informed consent form, voluntarily participate in and sign the informed consent form;\n2. Gender is not limited;\n3. Age: \u226518 years old and \u226475 years old (stage Ia); \u226518 years old (stage Ib);\n4. Locally advanced or metastatic breast cancer and other solid tumors;\n5. Must have at least one measurable lesion that meets the RECIST v1.1 definition;\n6. Have archived primary or recurrent tumor tissue specimens that can be submitted for central review;\n7. ECOG \u22641;\n8. The expected survival time as judged by the investigators was \u22653 months;\n9. Bone marrow function, renal function and liver function should meet the requirements;\n10. Coagulation function: fibrinogen \u22651.5g/L; Activated partial thromboplastin time (APTT) \u22641.5\u00d7ULN; Prothrombin time (PT) \u22641.5\u00d7ULN;\n11. Fertile female subjects or male subjects with fertile partners must use highly effective contraception from 7 days before the first dose until 12 weeks after the last dose. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose;\n12. Subjects were able and willing to comply with protocol-specified visits, treatment plans, laboratory tests, and other study-related procedures.\n\nExclusion Criteria:\n\n1. Chemotherapy, biological therapy, immunotherapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil;\n2. Patients with active infection requiring intravenous antibiotics who did not complete treatment within 1 week before enrollment, except prophylactic antibiotics for puncture or biopsy;\n3. Positive human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection or hepatitis C virus infection;\n4. No reduction in toxicity from previous antineoplastic therapy to grade I as defined in CTCAE, version 5.0, or to the level specified in the inclusion criteria;\n5. Patients at risk for active autoimmune disease or with a history of autoimmune disease may have central nervous system involvement;\n6. Pulmonary disease defined as \u2265 grade 3 according to NCI-CTCAE v5.0; A history of ILD requiring steroid therapy, or current ILD or grade \u22652 radiation pneumonitis;\n7. Patients with previous allogeneic hematopoietic stem cell transplantation or organ transplantation;\n8. Had a history of severe cardiovascular and cerebrovascular diseases;\n9. Patients had or had thrombotic events such as deep vein thrombosis, arterial thrombosis and pulmonary embolism within 6 months before screening;\n10. Brain parenchymal metastases and/or meningeal metastases or spinal cord compression, excluding stable and asymptomatic brain parenchymal metastases;\n11. Uncontrolled pleural effusion with clinical symptoms who were judged by the investigator to be ineligible for enrollment;\n12. Poorly controlled hypertension (systolic blood pressure \\&gt; 150 mmHg or diastolic blood pressure \\&gt; 100 mmHg);\n13. Who had participated in a clinical trial of an unmarketed drug within 4 weeks before the study dose (counted as the end of the last dose);\n14. Had received a live vaccine within 4 weeks before the trial dose;\n15. Other circumstances that the investigator deemed inappropriate for participation in the trial.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}